Success Stories: EB-1B Petition Approved for a Pharmacokineticist in Pennsylvania in the Field of Pharmaceutical Sciences

Client’s Testimonial:

 

Thank you very much for all the help. It's been a great journey with you! [...] I've already referred you to my friends. [...] I truly appreciate your efforts!

 


We Received EB-1B Approval for a Pharmacokineticist in the Field of Pharmaceutical Sciences on February 26th, 2015 (Approval Notice)


General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Pharmacokineticist

Petitioner: A Private Company

Country of Origin: China

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date:  February 26th, 2015

Processing Time:  28 days (9 days after Requesting Premium Processing)

 

 


Case Summary:

At North America Immigration Law Group, we recently received an EB-1B approval for a pharmacokineticist in the field of pharmaceutical sciences. The beneficiary’s outstanding ability, highly skilled background, and impressive record of achievement provided a strong case for her EB-1B petition. Her specialized research has focused on examining the causes of and the treatments for neurodegenerative disorders. Her research work had resulted in 4 peer-reviewed scientific articles, 2 peer-reviewed conference abstracts, 1 patent and 4 presentations at national and international conferences. She had also reviewed 35 manuscripts for journals at the time we filed the case. Furthermore, the beneficiary had a total of 91 citations to her work by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of her work. The petitioner in this case was a private company. The significance of the beneficiary’s research is confirmed in the following quote by an independent recommender, “In essence, [Client] has discovered the essential mechanisms in understanding the pharmacology of [therapeutic compound]. This enables a better understanding of past clinical trials where [therapeutic compound] was used in [disease]; and the discovered [therapeutic compound] mechanism of action is directly applicable not only to [disease] but also in a wide range of neurodegenerative disorders sharing similar pathophysiology.” It was our goal to prove that this beneficiary qualified for classification as an outstanding professor or researcher given the international recognition for her outstanding achievements.  With the proof and documentation that we provided, her case was approved in 28 days (9 days after requesting Premium Processing).